ClinicalTrials.gg
CompletedNCT01266148SCHEDULEUpdated Jun 10, 2015Results posted

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

A Phase 4 interventional study of Cyclosporine and Mycophenolate mofetil in Renal Function and Chronic Allograft Vasculopathy, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A controlled, randomized, open-label, multicenter study evaluating if early initiation of everolimus and early elimination of cyclosporine in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy

Read the detailed description

This was a prospective, multi-center, randomized, controlled, parallel group, open label study in de novo heart transplant recipients. Patients eligibility for randomization was assessed 5 days after heart transplant.. Patients fulfilling the inclusion and exclusion criteria were randomized to one of two treatment groups: either conventional treatment with Cyclosporine A (CsA), Mycophenolate mofetil (MMF), and corticosteroids (Group A), or low-dose CsA and everolimus, reduced dose MMF, and corticosteroids (Group B). After 7 to 11 weeks, CsA was discontinued in Group B, while the standard triple-drug immunosuppressive regimen was maintained in Group A.

02

Conditions studied

  • Renal Function and Chronic Allograft Vasculopathy
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

De novo heart transplant recipients who had received induction therapy with antithomocyte globulin (ATG) were eligible for inclusion.

Recipients of multi-organ transplants or a previous transplant were excluded, as were those with a donor aged > 70 years, cold ischemia time >6 hours, patients with severe systemic infection, recipients of ABO incompatible transplants, patients with severe hypercholesterolemia (>350mg/dL) or hypertriglyceridemia (>750 mg/dL), patients with past (\<5 years). In order to continue in the study after week 7-11 (period 1), patients had to complete first 7-11 weeks on randomized and none of the following criteria should be present: Ongoing rejection treatment or experience of one grade 3R rejection or two or more grade 2R rejections during first 7-11 weeks.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Everolimus

    Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.

    Drug: Cyclosporine · Drug: Mycophenolate mofetil · Drug: Corticosteroids · Drug: Everolimus · Drug: Anti Thymocyte Globulin

  • Experimental
    Control

    Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.

    Drug: Cyclosporine · Drug: Mycophenolate mofetil · Drug: Corticosteroids · Drug: Anti Thymocyte Globulin

Interventions

  • Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)

  • Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11

  • DrugCorticosteroids

    Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.

  • Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study

  • Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.

06

What researchers measure

Primary outcomes

  1. Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation

    Measured Glomerular Filtration Rate (mGFR) describes the flow rate of filtered fluid through the kidney. GFR is equal to the clearance rate when any solute is freely filtered and is neither reabsorbed nor secreted by the kidneys. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood. Participants' urine was used for this assessment at week 52 after heart transplant.

    Time frame: Week 52

Secondary outcomes

  1. Progression of Chronic Allograft Vasculopathy (CAV) Based on Maximal Intimal Thickness (MIT) From Baseline to Week 52

    The progression of chronic allograft vasculopathy (CAV) was assessed by intravascular ultrasound (IVUS) examinations and measured Maximal Intimal Thickness (MIT)(in mm). A major coronary epicardial artery (preferentially the left-anterior descending coronary artery) was imaged, and the MIT parameters were recorded at baseline and at week 52.

    Time frame: Baseline and week 52

  2. Progression of Chronic Allograft Vasculopathy (CAV) Based on Incidence of Chronic Allograft Vasculopathy (CAV) From Baseline to Week 52

    the progression of chronic allograft vasculopathy (CAV) assessed by intravascular ultrasound (IVUS) examinations, measured the incidence of CAV (in percent of patients) at baseline and at week 52. Incidence of CAV represents percent of patients having a MIT (maximal intima thickness) \> 0.5 mm.

    Time frame: Baseline and week 52

  3. Change in Calculated Glomerular Filtration Rate From Pre-transplantation to Week 52

    Change in calculated glomerular filtration rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end week 52.

    Time frame: Day 1, weeks 7 to 11(baseline) and of week 52

  4. Calculated Glomerular Filtration Rate From Pre-Transplantation to Week 52

    Calculated Glomerular Filtration Rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end of week 52.

    Time frame: Day 1, weeks 7 to 11 and of week 52

  5. Number of Rejections Leading to Hemodynamic Compromise

    Number of all rejections were recorded through the duration of the study with the intent to identify rejections leading to hemodynamic compromise.

    Time frame: 52 weeks

  6. Occurrence of Treatment Failures up to 12 Months After Transplant

    Treatment failure was defined as the number of participants who died or lost their graft at any timepoint througout the duration of the study.

    Time frame: 52 weeks

  7. Average Level of Protenuria at Week 52

    Proteinuria is measured as the ratio of albumin/creatinine mg/mmol. Measurements were taken from participants urine samples.

    Time frame: 52 weeks

  8. Lipid Profile at 12 Months

    Total Cholesterol, LDL-Chol, HDL-Chol and TG at week 52. Measurements were taken via participants blood samples.

    Time frame: 52 weeks

  9. Change in Quality of Life Assessed by SF-36 (Minnesota Living With Heart Failure Questionnaire ([MLHF)]) From Pre-transplant to Week 52 of Treatment

    Change in Quality of Life was assessed via the SF-36 (Minnesota Living with Heart Failure questionnaire (\[MLHF)\]) before transplant surgery and at week 52 of treatment. The SF-36 is a validated, self-administered questionnaire. The questionnaire, which includes 36 questions measures 8 dimensions of health: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. Scores can be summarized in 2 summary components assessing physical and mental health. Items in each dimension are coded, aggregated, summed, and transformed into a scale ranging from 0 (worse health) to 100 (best health).

    Time frame: Pre transplant and 52 weeks

  10. Change in Quality of Life - Euro Quality of Life 5D (EQ-5D)

    Change in Quality of Life was assessed via the EQ-5D questionnaire which consists of: EQ-5D-5L descriptive system and EQ Visual Analogue scale (EQ VAS). The EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The patient indicates his/her health state by checking the most appropriate statement. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions are combined in a 5-digit number describing the respondent's health state. The possible score is 1 to 5 where a lower number indicates improvement. The EQ VAS records the patient's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. The score is 0 to 100 where a higher score represents improvement.

    Time frame: Pre transplant and 52 weeks

07

Results

Posted May 13, 2014

Participant flow

115 patients (56 in the everolimus group, 59 in the control group) were randomized and received study treatment.

Participant flow — Overall Study
MilestoneEverolimusControl
Started5659
Completed4956
Not completed73
Withdrew: Adverse event20
Withdrew: Ongoing rejection10
Withdrew: 2 2r rejections10
Withdrew: Death23
Withdrew: Missing mgfr value + ae10

Outcome measures

PrimaryMeasured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation

Measured Glomerular Filtration Rate (mGFR) describes the flow rate of filtered fluid through the kidney. GFR is equal to the clearance rate when any solute is freely filtered and is neither reabsorbed nor secreted by the kidneys. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood. Participants' urine was used for this assessment at week 52 after heart transplant.

Time frame:
Week 52
Reported as:
Mean · mGFR ml/min
Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation
mGFR ml/minEverolimusControl
Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation79.8 ± 17.761.5 ± 19.6
SecondaryProgression of Chronic Allograft Vasculopathy (CAV) Based on Maximal Intimal Thickness (MIT) From Baseline to Week 52

The progression of chronic allograft vasculopathy (CAV) was assessed by intravascular ultrasound (IVUS) examinations and measured Maximal Intimal Thickness (MIT)(in mm). A major coronary epicardial artery (preferentially the left-anterior descending coronary artery) was imaged, and the MIT parameters were recorded at baseline and at week 52.

Time frame:
Baseline and week 52
Reported as:
Mean · mm
Progression of Chronic Allograft Vasculopathy (CAV) Based on Maximal Intimal Thickness (MIT) From Baseline to Week 52
mmEverolimusControl
Baseline (Week 7)0.52 ± 0.220.56 ± 0.24
Week 520.55 ± 0.240.65 ± 0.25
SecondaryProgression of Chronic Allograft Vasculopathy (CAV) Based on Incidence of Chronic Allograft Vasculopathy (CAV) From Baseline to Week 52

the progression of chronic allograft vasculopathy (CAV) assessed by intravascular ultrasound (IVUS) examinations, measured the incidence of CAV (in percent of patients) at baseline and at week 52. Incidence of CAV represents percent of patients having a MIT (maximal intima thickness) \> 0.5 mm.

Time frame:
Baseline and week 52
Reported as:
Number · Percentage of patients
Progression of Chronic Allograft Vasculopathy (CAV) Based on Incidence of Chronic Allograft Vasculopathy (CAV) From Baseline to Week 52
Percentage of patientsEverolimusControl
No CAV at baseline (week 7)43.547.9
CAV at baseline (week 7)56.552.1
No CAV at week 525035.4
CAV at week 525064.6
SecondaryChange in Calculated Glomerular Filtration Rate From Pre-transplantation to Week 52

Change in calculated glomerular filtration rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end week 52.

Time frame:
Day 1, weeks 7 to 11(baseline) and of week 52
Reported as:
Mean · mGFR mL/min
Change in Calculated Glomerular Filtration Rate From Pre-transplantation to Week 52
mGFR mL/minEverolimusControl
Day 1 (n= 43, 47)-13.0 ± 28.2-12.6 ± 32.6
Weeks 7 to 11 (n= 46, 49)7.4 ± 32.6-6.8 ± 26.2
Week 52 (n= 42, 53)27.8 ± 49.9-8.0 ± 28.3
SecondaryCalculated Glomerular Filtration Rate From Pre-Transplantation to Week 52

Calculated Glomerular Filtration Rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end of week 52.

Time frame:
Day 1, weeks 7 to 11 and of week 52
Reported as:
Mean · mGFR mL/min
Calculated Glomerular Filtration Rate From Pre-Transplantation to Week 52
mGFR mL/minEverolimusControl
Day 1 (n= 46, 48)65.4 ± 33.866.1 ± 28.7
Weeks 7 to 11 (n=50, 51)84.9 ± 40.569.6 ± 19.9
Week 52 (n= 45, 55)104.5 ± 54.069.3 ± 20.4
SecondaryNumber of Rejections Leading to Hemodynamic Compromise

Number of all rejections were recorded through the duration of the study with the intent to identify rejections leading to hemodynamic compromise.

Time frame:
52 weeks
Reported as:
Number · rejections
Number of Rejections Leading to Hemodynamic Compromise
rejectionsEverolimusControl
Total rejection185128
Treated rejection4317
Rejections with hemodynamic compromise00
SecondaryOccurrence of Treatment Failures up to 12 Months After Transplant

Treatment failure was defined as the number of participants who died or lost their graft at any timepoint througout the duration of the study.

Time frame:
52 weeks
Reported as:
Number · participants
Occurrence of Treatment Failures up to 12 Months After Transplant
participantsEverolimusControl
Treatment failure (death)23
Graff loss00
Total treatment failures (graft loss + death23
SecondaryAverage Level of Protenuria at Week 52

Proteinuria is measured as the ratio of albumin/creatinine mg/mmol. Measurements were taken from participants urine samples.

Time frame:
52 weeks
Reported as:
Mean · mg/mmol
Average Level of Protenuria at Week 52
mg/mmolEverolimusControl
Average Level of Protenuria at Week 527.2 ± 12.81.2 ± 1.4
SecondaryLipid Profile at 12 Months

Total Cholesterol, LDL-Chol, HDL-Chol and TG at week 52. Measurements were taken via participants blood samples.

Time frame:
52 weeks
Reported as:
Mean · mmol/L
Lipid Profile at 12 Months
mmol/LEverolimusControl
Total cholesterol5.3 ± 1.15.1 ± 1.0
LDL-C2.9 ± 1.02.8 ± 0.8
HDL-C1.6 ± 0.51.6 ± 0.5
SecondaryChange in Quality of Life Assessed by SF-36 (Minnesota Living With Heart Failure Questionnaire ([MLHF)]) From Pre-transplant to Week 52 of Treatment

Change in Quality of Life was assessed via the SF-36 (Minnesota Living with Heart Failure questionnaire (\[MLHF)\]) before transplant surgery and at week 52 of treatment. The SF-36 is a validated, self-administered questionnaire. The questionnaire, which includes 36 questions measures 8 dimensions of health: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. Scores can be summarized in 2 summary components assessing physical and mental health. Items in each dimension are coded, aggregated, summed, and transformed into a scale ranging from 0 (worse health) to 100 (best health).

Time frame:
Pre transplant and 52 weeks
Reported as:
Mean · Units on a scale
Change in Quality of Life Assessed by SF-36 (Minnesota Living With Heart Failure Questionnaire ([MLHF)]) From Pre-transplant to Week 52 of Treatment
Units on a scaleEverolimusControl
Physical Health pre- transplant30.8 ± 11.132.9 ± 8.0
Physical Health at week 5248.8 ± 9.648.8 ± 8.3
Mental Health pre- transplant46.2 ± 11.838.7 ± 12.4
Mental Health at week 5251.5 ± 12.253.9 ± 7.2
SecondaryChange in Quality of Life - Euro Quality of Life 5D (EQ-5D)

Change in Quality of Life was assessed via the EQ-5D questionnaire which consists of: EQ-5D-5L descriptive system and EQ Visual Analogue scale (EQ VAS). The EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The patient indicates his/her health state by checking the most appropriate statement. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions are combined in a 5-digit number describing the respondent's health state. The possible score is 1 to 5 where a lower number indicates improvement. The EQ VAS records the patient's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. The score is 0 to 100 where a higher score represents improvement.

Time frame:
Pre transplant and 52 weeks
Reported as:
Mean · Units on a scale
Change in Quality of Life - Euro Quality of Life 5D (EQ-5D)
Units on a scaleEverolimusControl
EQ-5D-5L pre- transplant (n=45,49)0.5750 ± 0.33870.5069 ± 0.3209
EQ-5D-5L at week 52 (n=41,44)0.8329 ± 0.26380.8367 ± 0.2234
EQ VAS pre- transplant (n=41,48)46.0 ± 24.338.9 ± 20.8
EQ VAS at week 52 (n=41,42)80.0 ± 15.079.4 ± 11.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Controls—27/59 (45.8%)53/59 (89.8%)
Everolimus—27/56 (48.2%)47/56 (83.9%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventControlsEverolimus
PneumoniaInfections and infestations1/595/56
Cardiac disorderCardiac disorders1/593/56
DiarrhoeaGastrointestinal disorders3/590/56
PyrexiaGeneral disorders3/590/56
Cytomegalovirus infectionInfections and infestations3/590/56
InfectionInfections and infestations3/591/56
DepressionPsychiatric disorders0/592/56
Pleural effusionRespiratory, thoracic and mediastinal disorders1/592/56
Multi-organ failureGeneral disorders2/591/56
EpilepsyNervous system disorders2/590/56
Most frequent other events
Showing 10 of 34
Most frequent other events
EventControlsEverolimus
HypertensionVascular disorders20/5910/56
Cytomegalovirus infectionInfections and infestations15/593/56
LeukopeniaBlood and lymphatic system disorders13/5911/56
Oedema peripheralGeneral disorders10/5912/56
Pleural effusionRespiratory, thoracic and mediastinal disorders7/5911/56
DiarrhoeaGastrointestinal disorders2/5910/56
InfectionInfections and infestations9/5910/56
NasopharyngitisInfections and infestations7/599/56
ArrhythmiaCardiac disorders9/596/56
AnaemiaBlood and lymphatic system disorders5/598/56

Baseline characteristics

Age, Continuous
Age, Continuous(years)EverolimusControlTotal
Mean51.02 ± 12.9351.47 ± 12.3651.25 ± 12.59
Sex: Female, Male
Sex: Female, Male(Participants)EverolimusControlTotal
Female171431
Male394584
08

Study locations

6 sites
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Århus N, DK-8200, Denmark
  • Novartis Investigative Site
    Oslo, 0424, Norway
  • Novartis Investigative Site
    Göteborg, 413 45, Sweden
  • Novartis Investigative Site
    Linkoping, 581 85, Sweden
  • Novartis Investigative Site
    Lund, 221 85, Sweden
09

References and documents

Publications

  • Arora S, Andreassen AK, Karason K, Gustafsson F, Eiskjaer H, Botker HE, Radegran G, Gude E, Ioanes D, Solbu D, Dellgren G, Ueland T, Aukrust P, Gullestad L; SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients. Circ Heart Fail. 2018 Sep;11(9):e004050. doi: 10.1161/CIRCHEARTFAILURE.117.004050. PubMed 30354362 ↗
  • Norum HM, Michelsen AE, Lekva T, Arora S, Otterdal K, Olsen MB, Kong XY, Gude E, Andreassen AK, Solbu D, Karason K, Dellgren G, Gullestad L, Aukrust P, Ueland T. Circulating delta-like Notch ligand 1 is correlated with cardiac allograft vasculopathy and suppressed in heart transplant recipients on everolimus-based immunosuppression. Am J Transplant. 2019 Apr;19(4):1050-1060. doi: 10.1111/ajt.15141. Epub 2018 Nov 5. PubMed 30312541 ↗
  • Andreassen AK, Broch K, Eiskjaer H, Karason K, Gude E, Molbak D, Stueflotten W, Gullestad L; SCHEDULE (SCandinavian HEart transplant everolimus De-novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators. Blood Pressure in De Novo Heart Transplant Recipients Treated With Everolimus Compared With a Cyclosporine-based Regimen: Results From the Randomized SCHEDULE Trial. Transplantation. 2019 Apr;103(4):781-788. doi: 10.1097/TP.0000000000002445. PubMed 30211826 ↗
  • Nelson LM, Andreassen AK, Andersson B, Gude E, Eiskjaer H, Radegran G, Dellgren G, Gullestad L, Gustafsson F. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation. Transplantation. 2017 Nov;101(11):2793-2800. doi: 10.1097/TP.0000000000001706. PubMed 28230646 ↗
  • Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L; SCHEDULE investigators. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study. Am J Transplant. 2016 Apr;16(4):1238-47. doi: 10.1111/ajt.13588. Epub 2016 Jan 28. PubMed 26820618 ↗
  • Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, Gude E, Jansson K, Solbu D, Sigurdardottir V, Arora S, Dellgren G, Gullestad L; SCHEDULE Investigators. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant. 2014 Aug;14(8):1828-38. doi: 10.1111/ajt.12809. PubMed 25041227 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2010
First posted
Dec 24, 2010
Start
Nov 2009
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
May 13, 2014
Last update
Jun 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01266148
Responsible party
Sponsor
First posted
Dec 24, 2010
Start date
Nov 2009
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
May 13, 2014
Last update
Jun 10, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion